Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics to $55 from $63 and keeps a Neutral rating on the shares. The analyst updated biotechnology models post the Q4 results.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRSP:
- Crispr Therapeutics initiated with a Buy at Bryan Garnier
- CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting
- Crispr Therapeutics CFO Brendan Smith to depart, Raju Prasad to succeed
- CRISPR Therapeutics Announces Transition of Chief Financial Officer
- Baird starts Crispr at Neutral with strong launch priced in